Literature DB >> 33539562

Non-dermatophyte fungi in onychomycosis-Epidemiology and consequences for clinical practice.

Dieter Reinel1.   

Abstract

Onychomycoses are difficult-to-treat fungal infections with a high recurrence rate that relates to the anatomic and pathophysiological conditions in the nail organ and the required extended duration of treatment. Clinical-epidemiological studies demonstrated that non-dermatophyte molds and yeasts are the primary causative agents in 20%-30% of onychomycoses. Mixed infections with dermatophytes are observed as well. Therefore, the causative agents should be determined by fungal culture and the antifungal treatment regimen should reliably cover non-dermatophytes, if appropriate. Systemic-topical combination therapy involving a broad-spectrum, locally applied antifungal may increase the mycological and clinical cure rates compared to monotherapy with systemic drugs.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  combination therapy; epidemiology; non-dermatophyte mold; onychomycosis; yeast

Year:  2021        PMID: 33539562     DOI: 10.1111/myc.13251

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  3 in total

1.  A Deep Learning Approach for Histopathological Diagnosis of Onychomycosis: Not Inferior to Analogue Diagnosis by Histopathologists.

Authors:  Florence Decroos; Sebastian Springenberg; Tobias Lang; Marc Päpper; Antonia Zapf; Dieter Metze; Volker Steinkraus; Almut Böer-Auer
Journal:  Acta Derm Venereol       Date:  2021-08-31       Impact factor: 3.875

2.  Combination of Photodynamic Therapy and Oral Antifungals for the Treatment of Onychomycosis.

Authors:  Alba Navarro-Bielsa; Tamara Gracia-Cazaña; Pilar Robres; Concepción Lopez; María Dolores Calvo-Priego; Carmen Aspiroz; Yolanda Gilaberte
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-07

3.  Combined laser and ozone therapy for onychomycosis in an in vitro and ex vivo model.

Authors:  Javier Fernández; Iván Del Valle Fernández; Claudio J Villar; Felipe Lombó
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.